RB1在恶性肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2016.01.017

摘要/Abstract

摘要： 视网膜母细胞瘤基因1(Retinoblastoma1,RB1)是人类发现的第一个抑癌基因,因为最初在视网膜母细胞瘤中发现该基因所以命名为视网膜母细胞瘤基因1。RB1作为一种负性调控因子在细胞周期中有重要作用,通过与转录因子E2F结合来调控细胞的增殖。研究还发现RB1在抗细胞凋亡中也扮演着重要的角色,RB1的敲除可以增强抗肿瘤药物导致细胞死亡的敏感性。RB1的这种双重作用提示其可能是恶性肿瘤的发病原因,并且可能成为肿瘤进展及临床治疗效果的预测指标。

关键词: RB1, 缺失, 低表达, 恶性肿瘤

Abstract: The RB1 gene is the first tumor suppressor gene identified whose mutational inactivation is the cause of a human cancer,the pediatric cancer retinoblastoma.As a negative regulator of the cell cycle,RB1 gene could regulate the expression of genes involved in cell proliferation through binding to transcription factor E2F.Among these,RB1 has been implicated in the regulation of apoptosis.RB1 knockdown has been shown to enhance the sensitivity to cell death induced by different anticancer agents.RB1 dual role in proliferation and apoptosis underlies malignant tumor occurrence,development and resistance totherapy.

Key words: RB1, Deficiency, Low expression, Malignant tumor

中图分类号:

孙志综述, 陈公琰审校. RB1在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2016, 30(1): 80-83.

SUN Zhi, CHEN Gongyan. The research progresses on RB1 in malignant tumors[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(1): 80-83.

参考文献

1 Modi S,Kubo A,Oie H,et al.Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer[J].Oncogene,2000,19(10):4632-4639.
2 Liu SH,Wang SZ,Zhang H.Research advances on rb1 gene[J].Hereditas,2010,32(11):1097-1104.
3 Valverde JR,Alonso J,Palaciosl I,et al.RB1 gene mutation update,a meta analysis based on 932 reported mutations available in a searchable database[J].BMC Genet,2005,6(20):53-58.
4 Tsai T,Fulton L,Smith BL,et al.Rapid identification of germline mutations in retino blastoma by protein truncation testing[J].Arch Ophthalmol,2004,122(2):239-248.
5 Du W,Pogoriler J.Retinoblastoma family genes[J].Oncogene,2006,25(38):5190-5200.
6 Miskolczi P,Lendvai A,Horvath GV,et al.Conserved functions of retinoblastoma proteins:from purple retina to green plant cells[J].Plant Sci,2007,172(4):671-683.
7 Sdek P,Zhao P,Wang Y,et al.RB and p130 control cell cycle gene silencing to maintain the postmitotic phenotype in cardiac myocytes[J].J Cell Bio,2011,194(3):407-423.
8 Indovina P,Pentimalli F,Casini N,et al.RB1 dual role in proliferation and apoptosis:Cell fate control and implications for cancer therapy[J].Oncotarget,2015,6(20):17873-17890.
9 Attardi LD,Sage J.RB goes mitochondrial[J].Genes Dev,2010,27(15):975-979.
10 Seong BK,Lau J,Adderley T,et al.SATB2 enhances migrateon and invasion in osteosarcoma by regulating genes involved in cytoskeletal organization[J].Oncogene,2015,34(27):3582-3592.
11 颜茂华,许斌,赵立来,等.微小RNA-144上调Rb抑制骨肉瘤细胞增殖及诱导凋亡[J].中国现代医生,2015,53(6):6-9.
12 Salinas Souza C,De Oliveira R,Alves MT,et al.The metastatic behavior of osteosarcoma by gene expression and cytogenetic analyses[J].Human Pathology,2013,44(10):2188-2198.
13 Kassahun WT,Jonas S.Focus on parathyroidcarcinoma[J].Int J Surg,2011,9(2):13-19.
14 Risoulidou A,Mandanas S,Mitsakis P,et al.Parathyroid involvement in thyroid cancer:all unforeseen event[J].World J Surg Oncol,2012,10(2):121-124.
15 Cetani F,Pardi E,Viacava P,et al.A reappraisal of the rb1 gene abnormalities in the diagnosis of parathyroid cancer[J].Clin Endocrinol,2004,60(1):99-106.
16 Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
17 Toyooka S,Mitsudomi T,Soh J,et al.Molecular oncology of Lung cancer[J].Gen Thorac Cardiovas Surg,2011,59(20):527-537.
18 Sutherland KD,Proost N,Brouns I,et al.Cell of origin of small cell lung cancer:inactivation of trp53 and Rb1 in distinct cell types of adult mouse lung[J].Cancer Cell,2011,19(6):754-764.
19 George J,Lim JS,Jang SJ,et al.Comprehensive genomic profiles of small cell lung Cancer[J].Nature,2015,524(7563):47-53.
20 Wei KR,Yu X,Zheng RS,et al.Incidence and mortality of liver cancer in China,2010[J].Chin J Cancer,2014,33(8):388-394.
21 Ahn SM,Jang SJ,Shim JH,et al.Genomic portrait of resectable hepatocellular carcinomas:implications of RB1 and FGF19 aberrations for patient stratification[J].Hepa-tology,2014,60(6):1972-1982.
22 Siegel R,Ward E,Brawley O,et al.Cancer statistics 2011[J].CA Cancer J Clin,2011,61(2):212-236.
23 杨力军,王禾,袁建林,等.前列腺癌p21CIP1/WAF1、Rb及PCNA的表达及意义[J].免疫学杂志,2006,22(5):538-541.
24 Rauh-Hain JA,Foley OW,Winograd D,et al.Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer[J].Am J Obstet Gynecol,2015,212(5):601-608.
25 Luvero D,Milani A,Ledermann JA.Treatment options in recurrent ovarian cancer:latest evidence and clinical potential[J].Ther Adv Med Oncol,2014,6(5):229-239.
26 黄宇婷,胡林萍,田著,等.上皮性卵巢癌中c-Myc基因扩增和Rb1基因缺失及临床意义[J].中国肿瘤临床,2012,39(20):1547-1555.
27 Kommoss S,Bois A,Ridder R,et al.Independent prognostic significance of cell cycle regulator proteins p16(INK4a)and pRb in advancedstage ovarian carcinoma including optimally debulked patients:a translational research subprotocol of a randomised study of the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study Group[J].Br J Cancer,2007,96(15):306-313.
28 郑莹,吴春晓,吴凡.中国女性乳腺癌死亡现况和发展趋势[J].中华预防医学杂志,2011,45(2):150-154.
29 赵云霞,龚晓萌,刘德纯,等.BRCA1、PTEN、Rb、C-myc、C-myb在乳腺癌中的异常表达及临床意义探讨[J].中国化学与细胞化学杂志,2012,21(1):57-62.
30 Treré D,Brighenti E,Donati G,et al.High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy[J].Ann Oncol,2009,20(11):1818-1823.
31 Agerbaek M,Alsner J,Marcussen N,et al.Retinoblastoma protein expression is an independent predictor of both radiation response and survival in muscle-invasive bladder cancer[J].Br J Cancer,2003,89(2):298-304.
32 Indovina P,Pentimalli F,Casini N,et al.RB1 dual role in proliferation and apoptosis:Cell fate control and implications for cancer therapy[J].Oncotarget,2015,6(20):17873-17890.

[1]	张茂祥,孙惠昕,宋冰冰. 2008—2012年哈尔滨市道里区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2019, 33(3): 261-265.
[2]	李诚, 兰莉, 杨超, 张婷婷, 王蕊, 林琳, 田文静. 2015—2017年哈尔滨市恶性肿瘤发病与死亡特征分析[J]. 实用肿瘤学杂志, 2019, 33(1): 62-66.
[3]	韩滕综述, 唐丽萍审校. PD-L1的表达与妇科恶性肿瘤预后关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 468-470.
[4]	韩帮岭, 汪亦民, 薛英威. 中性粒细胞与恶性肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 349-352.
[5]	周洁, 陈钰(综述), 陈道桢(审校). 纳米材料在肿瘤光动力治疗中的应用[J]. 实用肿瘤学杂志, 2018, 32(3): 245-249.
[6]	侯思宇(综述), 陈秀玮(审校). JMJD2B蛋白结构功能及在恶性肿瘤发生发展中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(3): 250-253.
[7]	张婷, 侯光营, 王鑫(综述), 贺岩(审校). QKI蛋白在恶性肿瘤中的研究进展及临床意义[J]. 实用肿瘤学杂志, 2018, 32(3): 263-266.
[8]	纪巧, 陈丽(综述), 何远桥(审校). 三维组织药敏法在肿瘤个体化精准医疗中的应用[J]. 实用肿瘤学杂志, 2018, 32(3): 280-284.
[9]	李静,张云艳. miR-331-3p在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 125-129.
[10]	张永欣, 黄河. Galectin-9与多种恶性肿瘤的研究进展及作用机制探讨[J]. 实用肿瘤学杂志, 2018, 32(2): 159-163.
[11]	吴逸飞, 刘宝刚. 硫氧还蛋白还原酶2在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 174-178.
[12]	韩雪娇, 李艳春, 孙立春, 鲁海玲审校. 14-3-3ζ与恶性肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 543-547.
[13]	江莹, 刘宝刚审校. RCAN1在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(6): 559-563.
[14]	孙禹琪,陈秀玮. CTGF/CCN2在恶性肿瘤的发生发展及靶向治疗中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 363-366.
[15]	霍明娟,孟祥程,孙影,程丽. ALCAM在妇科恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 381-384.